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Abstract 29 
Cyclosporine A (CsA) and sirolimus (SRL) are immunosuppressive agents (IA) associated 30 
with new-onset diabetes after transplantation (NODAT). This study aims to evaluate the 31 
effects of 3-weeks of treatment with either CsA (5 mg/kg BW/day) or SRL (1mg/kg BW/day) 32 
on insulin signaling and expression of markers involved in glucose metabolism in insulin-33 
sensitive tissues, in Wistar rats.   34 
Although no differences were observed in fasting glucose, insulin or C-peptide levels, both 35 
treated  groups displayed an impaired glucose excursion during both glucose and insulin 36 
tolerance tests. These results suggest glucose intolerance and insulin resistance.  37 
An increase in glucose-6-phosphatase protein levels (68%, p<0.05) and in protein-tyrosine 38 
phosphatase 1B (163%, p< 0.05), a negative regulator of insulin was observed in the CsA-39 
treated group in the liver, indicating enhanced gluconeogenesis and increased insulin 40 
resistance. On the other hand, glucokinase protein levels were decreased in the SRL group 41 
(35%, p<0.05) compared to vehicle, suggesting a decrease in glucose disposal. SRL treatment 42 
also reduced peroxisome proliferator-activated receptor γ coactivator 1 alpha protein 43 
expression in muscle (∼50%, p<0.05), while no further protein alterations were observed in 44 
muscle and perirenal adipose tissue nor with the CsA treatment. Moreover, the 45 
phosphorylation of key proteins of the insulin signaling cascade was suppressed in the SRL 46 
group, but was unchanged by the CsA treatment.  47 
Taken together, these data suggest that CsA treatment enhances gluconeogenic factors in 48 
liver, while SRL treatment impairs insulin signaling in peripheral tissues, which can 49 
contribute to the development of insulin resistance and NODAT associated with 50 
immunosuppressive therapy. 51 
Keywords: immunosuppressive agents, insulin signaling, gluconeogenesis, adipocyte, 52 
muscle, liver 53 
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List of abbreviations 54 
 55 
Akt  Protein kinase B 56 
AS160  Protein kinase B substrate of 160 kDa 57 
CsA  Cyclosporine A 58 
FKBP12         FK506-binding protein (12-kD) 59 
FOX  Forkhead box  60 
GK  Glucokinase 61 
GLUT  Glucose transporter 62 
G6P  Glucose-6 phosphate 63 
G6Pase Glucose-6-phosphatase 64 
IR  Insulin receptor 65 
IRS  Insulin receptor substrate 66 
mTOR  Mammalian target of rapamycin 67 
NODAT New onset diabetes after transplantation 68 
p70S6K p70 ribosomal S6 kinase 69 
PDK1  Phosphoinositide-dependent kinase 1 70 
PEPCK Phosphoenolpyruvate carboykinase 71 
PI3K  Phosphatidylinositol 3-kinase 72 
PGC1-α Peroxisome proliferator-activated receptor- coactivator  73 
PTP1B Protein-tyrosine phosphatase 1B 74 
SRL  Sirolimus 75 
 76 
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1. Introduction  77 
Immunosuppressive therapy is used in the treatment of autoimmune diseases and after organ 78 
transplantation, to promote tolerance to allografts [1]. Two of the main immunosuppressive 79 
agents are cyclosporine A (CsA) and sirolimus (SRL). CsA is a peptide of fungal origin that 80 
forms a complex with its intracellular receptor, cyclophilin A, an important intracellular 81 
acceptor protein with peptidyl-prolyl cis-trans isomerases (PPIase) activity [2]. Consequently, 82 
the drug-immunophilin complex binds to and inhibits the serine-phosphatase activity of 83 
calcineurin required for T-cell activation. Prevention of the calcineurin-mediated 84 
dephosphorylation of the transcription nuclear factor of activated T-cells, blocks its 85 
translocation to the nucleus.  Interleukin (IL)-2 production is inhibited and, consequently also 86 
the proliferation and differentiation of T-cells [1, 3]. On the other hands, SRL, an antifungal 87 
macrolide, binds to the 12-kD FK506-binding protein (FKBP12) and this complex inhibits the 88 
target of rapamycin (TOR) Ser/Thr kinase. As mTOR regulates mRNA translation initiation 89 
and progression from the G1 to S phase of the cell cycle, its inhibition prevents T-cell 90 
proliferation [4]. 91 
Although these immunosuppressive agents are very effective in their function, they are also 92 
responsible for the development of metabolic complications, linked to higher rates of 93 
cardiovascular disease and infections, which are the major causes of morbidity and mortality 94 
after transplantation [5-7]. One of the complications is NODAT, usually manifested in the 95 
first few months post-transplantation and varying according to the type of immunosuppressive 96 
agent, their different combinations and patient demographics [8]. NODAT is reported in 2.5 97 
to 40% of patients that underwent renal, liver, heart or lung transplant [9]. Similar to type 2 98 
diabetes, NODAT has been associated with impairment in glucose tolerance, insulin secretion 99 
and dysfunctional hepatic gluconeogenesis [10]. Insulin directly regulates gluconeogenesis, 100 
however in insulin resistance states it does not properly suppresses gluconeogenesis in the 101 
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liver, leading to enhanced activation of forkhead box-containing transcription factors of the 102 
FOXO subfamily, promoting increased  transcription of glucose-6-phosphatase (G6Pase) and 103 
phosphoenolpyruvate  carboxykinase (PEPCK),  rate-limiting enzymes in hepatic 104 
glycogenolysis and gluconeogenesis, respectively [11, 12]. Moreover, according to Ropelle et 105 
al. [13] the physical interaction of peroxisome proliferator-activated receptor γ coactivator 1 106 
(PGC-1α) and FOXO1 promote an important signal transduction pathway responsible for the 107 
synthesis of glucose by the liver. Furthermore, PGC-1α expression is a tissue-specific 108 
regulatory marker activated in diabetic states, as well as the fasted state. It is perhaps 109 
responsible for increased hepatic glucose production and consequently hyperglycemia [13, 110 
14], making it a marker of interest together with its downstream targets.  111 
On the other hand, insulin participates in many physiological processes, particularly important 112 
in maintaining glucose homeostasis. After a meal, glucose increases in circulation, stimulating 113 
the secretion of C-peptide and insulin, which inhibit glycogenolysis and gluconeogenesis, 114 
promoting at the same time glycogen synthesis and glucose uptake. Insulin binds to its cell 115 
surface receptor (IR), activating its intrinsic tyrosine kinase activity and leading to receptor 116 
auto-phosphorylation, which in turn leads to the phosphorylation of insulin receptor substrates 117 
proteins (IRS-1 – IRS-4). As a result, several downstream signaling pathways are activated, 118 
including the p85 regulatory subunit of PI3-kinase and protein kinase B (Akt/PKB). This last 119 
step activates pyruvate dehydrogenase kinase 1 (PDK1) and protein kinase C (PKC), leading 120 
to the translocation of the muscle and fat specific glucose transporter (GLUT)4 from 121 
intracellular vesicles to the plasma membrane [15]. Alterations in these signaling pathways 122 
may affect glycemia and lead to unwanted metabolic consequences like diabetes and 123 
dyslipidemia [15]. Although CsA and SRL have been linked with NODAT, the underlying 124 
mechanisms are still not completely understood. SRL has been shown to improve insulin-125 
stimulated glucose uptake and Akt/PKB phosphorylation in L-6 muscle cells, 3T3-L1 cells 126 
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and in differentiated adipocytes [16-18], while other studies have shown reduced glucose 127 
uptake [19] and Akt/PKB phosphorylation in human mature adipocytes [20]. On the other 128 
hand, while immunosuppressive agents like CsA have been involved in the inhibition of the 129 
phosphorylation of the IR, it has not been associated with alterations in the expression or 130 
phosphorylation of proximal insulin signaling cascade proteins (Pereira et al., unpublished 131 
data), [21]. Therefore, there is still a lack of consensus regarding the underlying mechanism 132 
for NODAT caused by both CsA and SRL.  133 
Recently, we and others have reported that treatments with either CsA or/and SRL leads to 134 
metabolic alterations in liver, muscle and adipose tissue and possibly contribute to the 135 
development of dyslipidemia and insulin resistance associated with immunosuppressive 136 
therapy; however no insulin signaling studies have been performed to unravel the underlying 137 
mechanisms in these tissues [5, 19, 22-24]. Therefore, the main aim of this in vivo study is to 138 
understand how these immunosuppressive agents affect gluconeogenesis and insulin signaling 139 
in liver, muscle and adipose tissue after 3 weeks of treatment, in a rodent model. 140 
 141 
2. Materials and methods 142 
 143 
2.1 - Chemicals  144 
CsA (Sandimmune Neoral®) was supplied by Novartis Pharma (Lisbon, Portugal) and SRL 145 
(Rapamune®) by Wyett Europe Ltd (Berkshire, United Kingdom) through the Pfizer 146 
Laboratories Lda (Lisbon, Portugal). Human insulin, Actrapid was kindly provided by 147 
NovoNordisk A/S (Lisbon, Portugal). Ketamine (Ketalar®, Parke-Davis) was purchase from 148 
Pfizer Labs, while chlorpromazine (Largatil®, Rhône-Poulenc Rorer) was from Vitória labs 149 
(Amadora, Portugal). The High Capacity cDNA Reverse Transcription kit was obtained from 150 
Applied Biosystems (Forest City, CA, USA) and the RNeasy® MiniKit and the QIAzol® 151 
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Lysis Reagent from QIAGEN Sciences (Germantown, MD, USA). Diethyl pyrocarbonate 152 
(DEPC) was acquired from AppliChem (Darmstadt, Germany). Methanol, isopropanol and 153 
chloroform were obtained from Merck (Darmstadt, Germany). PCR primers were designed by 154 
us, using Vector NTI Advanced 10 Software (Life technologies, Grand Island, NY, USA) and 155 
were synthesized by Integrated DNA Technologies, Inc (IDT, Coralville, IA, USA). 156 
 157 
2.2 - Animals and treatments 158 
Male Wistar rats, weighing ~300 g, 10 weeks old, were obtained from Charles River Lab. Inc. 159 
(Barcelona, Spain). Animal studies were conducted using protocols approved by to the 160 
National and European Community Council Directives on Animal Care. The animals were 161 
housed in a light-controlled 12 h dark/light cycles and were given standard laboratory chow 162 
(IPM-R20, Letica, Barcelona, Spain) and free access to tap water.  Body weight was 163 
monitored every week [19]. 164 
Animals were randomly divided into three groups (n=16 per group): Vehicle (orange juice); 165 
CsA – 5 mg/kg body weight (BW)/day of Sandimmune Neoral® and SRL – 1 mg/kg BW/day 166 
of Rapamune®. The agents were diluted in orange juice as is the usual procedure in the clinic 167 
for the patients [25]. The use of a diluted form of orange juice was applied to vehicle and CsA 168 
and SRL-treated rats eliminating or highly minimizing any possible effect in glucose 169 
metabolism. Doses were chosen to have blood concentration achieved within the 170 
recommended therapeutic windows for CsA and SRL [19]. Treatments were performed daily 171 
by esophageal gavage for 3 weeks. At the end of the treatments, rats were anesthetized i.p. 172 
with 2 mg/kg/BW of a 2:1 (v:v) Ketamine solution in 2.5% Chlorpromazine. In each group, 8 173 
animals received a bolus of insulin - Actrapid (i.p 10 U/kg) and were sacrificed 10 minutes 174 
later in order to study insulin action in vivo, in the insulin sensitive tissues. The other 8 175 
animals received saline as a control. Blood samples were collected from the jugular vein for 176 
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biochemical analysis and liver, skeletal muscle (posterior thigh of the rat leg), perirenal and 177 
epididymal adipose tissues were rapidly harvested and frozen in liquid nitrogen for further 178 
analyses. Liver, muscle, epididymal and perirenal adipose tissues were used to perform 179 
quantitative RT-PCR and western blots. Epididymal adipose tissue was used for insulin 180 
signaling to be correlated with the insulin-stimulated glucose uptake results assessed and 181 
presented in our previous work [19]. 182 
  183 
2.3 – Glucose and insulin tolerance tests, fasting serum glucose, insulin, C-peptide and 184 
glycogen measurements 185 
A glucose tolerance test (GTT) and an insulin tolerance test (ITT) were performed at the end 186 
of 3 weeks of treatments. A glucose solution was injected (i.p. 2 g/kg BW) after a 16 hour 187 
fasted for the GTT and for the ITT, a solution of insulin (i.p 1 U/kg BW; Actrapid) diluted in 188 
saline 0.9% (w/v) after a 6 hour period of fasting. Blood was collected from the tail vein prior 189 
to (0 min) and at the various times after injection, as indicated in figure 1 A and B. Blood 190 
glucose levels were measured using a glucometer (AccuChek Active, Roche Diagnostics®, 191 
Indiana, USA). From fasting serum samples collected on the day of sacrifice, C-peptide and 192 
insulin were determined by an ELISA kit (Mercodia, Uppsala, Sweden). Liver tissue was 193 
prepared according to the manufacturer´s instructions. Aliquots were centrifuged at 18,000 × 194 
g for 10 min and the supernatants were used to analyze glycogen concentration using a kit 195 
(Abnova, VWR international, Carnaxide, Portugal).  196 
 197 
 198 
2.3.1 – Glucose clearance rate in the urine 199 
Animals (n=6/group) were housed in metabolic cages during 24 hours and received tap water 200 
and food ad libitum. The 24 hour urine was collected, volume was measured and glucose 201 
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concentration was determined using Cobas Integra® 400 plus (Roche Diagnostics®, Indiana, 202 
USA ), in order to calculate the glucose clearance rate. 203 
 204 
2.6 - Liver, muscle and adipose tissue gene expression  205 
Total RNA from liver, muscle and perirenal adipose tissue was isolated with RNeasy Mini Kit 206 
and the concentration was determined by OD260 measurement using the NanoDrop 207 
spectrophotometer (Thermo Scientific, USA). cDNA synthesis was performed using the High 208 
Capacity cDNA Reverse Transcriptase kit (Applied Biosystems; Forest City, CA, USA). 209 
Relative mRNA levels were measure by RT-PCR using specific primers for each target 210 
mRNA and Sybr-green PCR mix (Quanta Biosciences, Inc., Gaithersburg, MA, USA) with a 211 
CFX Manager TM version 2.0 Real-Time PCR detection system (Bio-Rad Laboratories, 212 
Hercules, CA, USA). Quantitative RT-PCR results were analyzed through delta CT 213 
calculations. Relative mRNA levels for the different genes:  FOXO1 (FOXO1); PGC1-α 214 
(PPARGC1A); PTP1B (PTPN1); Glucose-6-phosphatase (G6PC); Phosphoenolpyruvate 215 
carboxykinase (PCK); Glucokinase (GCK); Insulin receptor (INSR); IRS-1 (IRS-1); GLUT1 216 
(SLC2A1); GLUT2 (SLC2A2); GLUT4 (GLUT4) were determined and normalized using both 217 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and TATA – binding protein (TBP) 218 
mRNA levels. All primer sequences are available upon request. 219 
 220 
2.5. Tissue lysates and immunoblotting 221 
Liver, muscle, perirenal and epididymal adipose tissues were homogenized and total protein 222 
was extracted in lysis buffer (25 mM, Tris-HCl (pH 7.4), 0.5 mM EDTA, 25 mM NaCl, 1% 223 
(v/v), Nonidet P-40, 1 mM Na3VO4, 10 mM NaF, 10 mM Na4P2O7 and protease inhibitors - 224 
Sigma, St. Louis, MO, USA). Aliquots of total lysate were subjected to SDS-PAGE, 225 
transferred to a PVDF membrane and immunoblotted with the primary antibody according to 226 
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the manufacturer’s instructions, and thereafter incubated with the appropriate secondary 227 
antibody. The primary antibodies IR Tyr1146, IRS-1, PI3Kp85, FOXO1, Akt Ser473, Akt 228 
Total, p70S6KThr 421/424, p70S6K, AS160 Ser642 and mTOR were purchased from Cell 229 
Signaling Technologies (Beverly, MA, USA). The primary antibodies Akt Thr308, G6Pase, 230 
PEPCK, GK, PTP1B were acquired from Santa Cruz Biotecnology, Inc. (Dallas, Texas, 231 
USA); GLUT1, GLUT2, GLUT4, Akt 2/β, mTOR Ser2448, AS160 total were purchased from 232 
Millipore (Billerica, MA, USA); and IRS-1 Tyr612 was from Invitrogen (Life Technologies, 233 
Carlsbad, CA, USA). Protein expression was normalized using either α-tubulin (Cell 234 
Signaling Technologies) or the β-actin antibodies (Sigma) to avoid overlap of bands. 235 
Detection was performed by using Enhanced ChemiFluorescence (ECF) (GE Healthcare Bio-236 
Science, Pittsburgh, PA, USA) and the generated signals were analyzed using the Image 237 
LabTM 4.1 TMsoftware (Bio-Rad Laboratories, Hercules, CA, USA).   238 
 2.6 - Statistical Analysis 239 
Statistical analyses were performed using the GraphPad Prism software, version 5 (GraphPad 240 
Software Inc., La Jolla, CA, USA).  Results are given as mean ± standard error of the mean 241 
(SEM). Differences between groups were tested by performing analysis of variance (One-242 
Way ANOVA) and differences between basal and insulin stimulated phosphorylation were 243 
assessed through the unpaired Student-t-test.  A p<0.05 was considered statistically 244 
significant. 245 
 246 
3 -Results 247 
3.1 GTT, ITT, glucose, insulin, C-peptide in serum and glycogen measurements in liver 248 
GTTs were performed at the end of the treatments. The measurements revealed that glucose 249 
tolerance was impaired in the CsA-treated animals. The CsA-treated group displayed a peak 250 
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of glucose (18.62 ± 1.80 mmol/l) 15 minutes after the glucose bolus (2 g/kg BW, i.p.), when 251 
compared to either the vehicle group (11.16 ± 1.56 mmol/l, p<0.001) or the SRL-treated 252 
group (10.97 ± 1.68 mmol/l; p<0.001) (Fig 1A). However no significant differences were 253 
observed in the remaining time points during the GTT between the vehicle and the SRL 254 
groups. The glucose excursion curve for SRL was also impaired and the recovery kinetics of 255 
the blood glucose levels was significantly slower. Furthermore, the ITT curve revealed that 256 
insulin sensitivity was impaired in the CsA treated animals (Fig 1B). For the SRL group, a 257 
significant increase in blood glucose levels during an ITT was only observed at 60 min (3.76 258 
± 0.08 mmol/l) compared to the vehicle group (2.65 ± 0.14 mmol/l, p<0.05). Although, no 259 
significant differences were found in the AUC for the GTT (Fig. 1A), the AUC for the ITT 260 
was 67% (p<0.001) and 55% (p<0.001) increased in CsA and SRL-treated groups, compared 261 
to vehicle (Fig. 1 B). This result further confirmed reduced insulin sensitivity for both the 262 
CsA and SRL-treated animals. No significant differences were found in the glucose or insulin 263 
levels in the fasted state between groups. A non-significant decrease in fasting C-peptide 264 
levels was observed in both treated groups (Fig. 1C, D and E). The liver glycogen content was 265 
0.61 ± 0.03 µg/µl in the vehicle group and it was not significantly different between the CsA- 266 
and the SRL-treated groups (0.55± 0.03 and 0.52 ± 0.04, respectively).  267 
 268 
3.1.2 Glucose clearance rate in the urine  269 
Animals in the SRL group exhibited a trend for an increased glucose clearance rate (0.14 270 
±0.04 ml/h/rat), compared with the CsA (0.06 ± 0.01 ml/h/rat; p=0.06) but no significant 271 
difference compared with the vehicle-treated group with the present study power (0.09 ± 0.01 272 
ml/h/rat). This result suggests that an excess of glucose is present in the urine flux and is 273 
being expelled via the kidneys (Fig. 1F). 274 
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3.3 Effect of CsA and SRL on protein and gene expression in liver 275 
 276 
3.3.1 Gluconeogenesis is modulated by either CsA or SRL 277 
 278 
To evaluate if CsA or SRL treatment affects gluconeogenesis, we evaluated liver expression 279 
levels of some of the important key players. Although no significant changes were observed 280 
in the transcription factors PGC1-α and FOXO1 at gene level, a tendency for an increase in 281 
the protein expression was observed in the CsA group (PGC1-α p=0.09) (Fig. 2A). Moreover, 282 
a significant increase in protein expression for G6Pase, an enzyme that regulates hepatic 283 
gluconeogenesis, was observed in the CsA group (p<0.05) compared with the vehicle group 284 
(Fig.2B). No significant differences were observed for PEPCK both for gene and protein 285 
expression in the same group (Fig. 2B). The expression of GK protein, an important 286 
contributor for the formation of glycogen and responsible for the phosphorylation of glucose 287 
into glucose-6-phosphate, was not changed in the CsA group, but was significantly decreased 288 
in the SRL group (35%, p<0.05) (Fig. 2B). 289 
Moreover, we evaluated PTP1B expression, an important marker that negatively regulates 290 
insulin action, and found a significant increase in protein levels in the CsA group (163%, p< 291 
0.05) when compared to the vehicle group (Fig. 2A).  292 
 293 
3.3.2 Effects of CsA and SRL on insulin signaling in the liver  294 
 295 
To further elucidate signaling events that might promote the impaired glycemia and insulin-296 
stimulated glucose uptake observed in our previous work [19], we evaluated the activation of 297 
important insulin signaling markers. Total IRS-1 protein level was increased in the SRL group 298 
(49%, p<0.05), while GLUT1 tended to decrease in the same group (Fig. 3A). No significant 299 
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changes were observed in the gene levels for IRS-1, GLUT1 and GLUT2 in both treated 300 
groups compared to vehicle (Fig. 3A). Insulin stimulation significantly increased 301 
phosphorylation of IRS-1 at Tyr612 and Akt at both Ser473 and Thr308, but no significant 302 
differences were found for IR at Tyr1146, IRS-1 at Tyr612, mTOR at Ser2448 and p70S6K at 303 
Thr421/424 (Fig 3B). SRL treatment reduced phosphorylation of all studied insulin signaling 304 
proteins, while CsA did not affect phosphorylation of any of the proteins analyzed. Total 305 
protein levels of the respective markers were not affected by either treatment. 306 
 307 
3.4 Effects of CsA and SRL on protein and gene expression in muscle 308 
 309 
3.4.1 SRL decreases PGC1-α in muscle. 310 
 311 
SRL treatment reduced PGC1-α protein expression in muscle (∼50%, p<0.05), compared to 312 
the vehicle group (Fig. 4A), while CsA had no effect. No changes were found for FOXO1 and 313 
PTP1B gene and protein expression with either treatment.  314 
 315 
3.4.2 Effect of CsA and SRL on insulin signaling in muscle  316 
 317 
We further evaluate the effects of CsA and SRL treatment on insulin signaling in muscle. No 318 
significant changes were found in gene expression for either IRS-1 or GLUT4, while GLUT1 319 
was significantly increased in the CsA group (p<0.03). Furthermore, there were no significant 320 
differences for IRS-1 and GLUT1 protein levels in the SRL group, and no changes were 321 
observed in GLUT4 protein expression in either treated group (Fig. 5A). To determine 322 
whether a therapeutic dose of these IAs would affect insulin signaling in muscle, the 323 
phosphorylation of important key players were assessed. Insulin stimulation significantly 324 
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increased phosphorylation of IRS-1 at Tyr612 and Akt at both Ser473 and Thr308 (Fig 5B). 325 
SRL treatment reduced phosphorylation of IRS-1 at Tyr612, Akt at Thr308, mTOR at 326 
Ser2448 and p70S6K at Thr421/424, compared with the vehicle group. On the other hand, 327 
while no changes were observed for Akt phosphorylation on Ser473 by CsA treatment, Akt 328 
Thr308 phosphorylation was impaired. However, the total protein levels of these markers 329 
were not altered by either treatment (Fig. 5 B).  330 
 331 
3.5 Effect of CsA and SRL on protein and gene expression in adipose tissue 332 
 333 
3.5.1 Neither CsA nor SRL affected PTP1B, PGC1-α, or FOXO1 protein levels in perirenal 334 
adipose tissue  335 
 336 
In perirenal adipose tissue, although SRL treatment reduced the gene expression of PGC1-α 337 
(61%, p<0.05) compared to the vehicle group, protein levels were similar between the groups. 338 
Moreover, no changes were found for either FOXO1 or PTP1B gene or protein expression 339 
levels in this tissue (Fig. 6A).  340 
 341 
3.5.2 Effects of CsA and SRL on insulin signaling in adipose tissue 342 
 343 
We further evaluate the effects of CsA and SRL treatment on insulin signaling in adipose 344 
tissue. In perirenal adipose tissue, no changes were observed in IR or IRS-1 gene (Fig. 7A), or 345 
protein levels in the SRL treated group. No significant changes were either observed for 346 
GLUT1 and GLUT4 gene or protein levels in the SRL group, at the present study power. CsA 347 
treatment did not affect gene or protein expression for IR, IRS-1, GLUT1 or GLUT4 (Fig. 348 
7A). 349 
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In epididymal adipose tissue, insulin stimulation significantly increased phosphorylation of IR 350 
at Tyr1146, IRS-1 at Tyr612 and Akt at Ser473 (Fig 7B). Treatments with both CsA and SRL 351 
significantly impaired phosphorylation of IR Tyr1146 residue compared to vehicle. On the 352 
other hand, SRL treatment reduced Akt phosphorylation at Ser473, mTOR at Ser2448 and 353 
p70S6K at Thr421/424, compared with the vehicle group (Fig. 7B). Total proteins levels were 354 
not altered by either treatment. 355 
 356 
Discussion 357 
The present study indicates that an in vivo 3 week-treatment of Wistar rats with either CsA or 358 
SRL impairs glucose metabolism. Treatment with CsA resulted in impaired glucose tolerance 359 
and insulin sensitivity as demonstrated during a GTT and an ITT, respectively. Moreover, 360 
treatment with CsA increased protein expression of key enzymes for hepatic gluconeogenesis, 361 
G6Pase and PEPCK, and the upstream transcription factors PGC1-α and FOXO1 were also 362 
increased in the liver, providing insight into the molecular mechanisms for the elevation of 363 
glucose in the blood. Moreover, PTP1B protein levels were also increased in the liver in the 364 
CsA-treated group, which may contribute to impaired insulin sensitivity observed during the 365 
treatment. Although SRL had no effect on the expression of genes or proteins involved in 366 
gluconeogenesis in the liver, it significantly decreased GK protein expression, an enzyme 367 
responsible for the phosphorylation of glucose to glucose-6-phosphate, possibly leading to 368 
decreased glucose disposal. In addition, the effects of these agents on activation of insulin 369 
signaling in the liver, muscle and adipose tissue were evaluated. SRL treatment reduced Akt 370 
phosphorylation in these tissues, leading to reduced AS160 phosphorylation. These effects 371 
combined might impair GLUT4 translocation, which we did not measured for lack of tissue, 372 
explaining the reduction in glucose uptake observed previously [19]. Altogether, these results 373 
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suggest that CsA and SRL modulate glucose metabolism and insulin action, although through 374 
different mechanisms, i.e. while CsA seems to enhance gluconeogenesis, SRL mainly impairs 375 
insulin signaling in peripheral tissues. These effects might contribute to the development of 376 
insulin resistance and NODAT observed during immunosuppressive therapy. 377 
Body weight was monitored weekly as presented in our previous work [19].While, the CsA 378 
group presented a weight gain similar to vehicle, SRL gained less weight. Although food 379 
intake was not measured, other authors have observed reduced food intake and food 380 
efficiency with a higher dose of rapamycin (2mg/kg/day) [26, 27]. 381 
The CsA group presented impaired glucose tolerance during a GTT when compared to either 382 
the vehicle or the SRL-treated groups. The latter, also presented an impaired glucose 383 
excursion curve. As normal insulin action is required for clearing an oral glucose load [28], 384 
this impairment might be due to reduced insulin secretion by β-cells and/or a reduction in 385 
peripheral insulin sensitivity [5, 29] in the CsA-treated group. This was confirmed after an 386 
ITT, as even when an exogenous insulin bolus was administered, the glucose levels in the 387 
CsA group remained higher, and the rate of glucose disposal to reach basal levels was slower. 388 
This is also true for the SRL group, in particular at the 60 minutes time point where the 389 
glucose values were significantly higher than vehicle and closer to those of the CsA group. In 390 
fact, the presence of higher levels of insulin was not sufficient to decrease glucose levels 391 
similar to the ones observed in the vehicle group, suggesting marked insulin resistance in both 392 
CsA and SRL treated groups. Furthermore, to evaluate if this could be due to impaired insulin 393 
secretion from the β-cells of the islets of Langerhans, after 3 weeks of treatment with 394 
therapeutic doses, we measured insulin and C-Peptide levels. However, no differences were 395 
observed for insulin, and even thought C-peptide levels were reduced, there were not 396 
statistically significant. This condition is usually associated with induced diabetes in rats [30] 397 
and a defect in β-cells [31]. 398 
Page 17 of 41
Ac
ce
pte
d M
an
us
cri
pt
17 
 
SRL is considered to be less nephrotoxic than CsA, and is presently a valid option instead of 399 
calcineurin inhibitors for the maintenance of immunosuppression [32]. Therefore, we also 400 
evaluated if the clearance of glucose rates in the urine was impaired. Surprisingly, we found a 401 
tendency for an increase in the glucose clearance rate in the SRL treated group, which might 402 
be related to an increase of glucose in the urine, in greater quantities than the renal tubule can 403 
absorb (glycosuria), and this condition has already been observed in patients under SRL 404 
therapy [33]. No difference was observed in the CsA group, but as Yale, Roy [34] have 405 
shown, it requires higher doses and duration of treatment to cause glycosuria with CsA 406 
(e.g.10 mg/kg BW/day for 12 weeks). 407 
Moreover, as the development of insulin resistance has been linked to enhanced hepatic 408 
gluconeogenesis, we evaluated some of the key markers of this pathway. In our model, after 3 409 
weeks of treatment with CsA, G6Pase protein levels were significantly increased and were 410 
accompanied by non-significant increase in protein expression for PEPCK and transcription 411 
factors PGC1-α and FOXO1, confirming an overstimulated hepatic gluconeogenesis. In the 412 
SRL group, we did not observe an increase in gluconeogenesis, as reported previously by 413 
Houde, Brûlé [26] and Lamming, Ye [35]. This apparent discrepancy might be dose-related, 414 
as the authors used a higher dose of SRL. Interestingly, although no changes were observed in 415 
GK gene expression, an enzyme responsible for producing glucose-6-phosphate, GK protein 416 
levels were decreased in the SRL-treated group. This might cause impairment in glucokinase 417 
activity, reducing the glucose disposal in the liver. However, no differences were found in 418 
glycogen content in the liver between the treated groups, in agreement with Houde, Brûlé [26] 419 
and Pfaffenbach, Nivala [36]. In addition, GK is controlled at the transcriptional level in a 420 
TORC1-dependent manner [37] and therefore assays to determine GK activity should be 421 
considered in future studies with SRL treatment. Moreover, gene and protein levels for 422 
PGC1-α and FOXO1 were also measured in muscle and perirenal adipose tissue, where their 423 
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actions are more linked to their role in mitochondrial biogenesis, myogenesis and adipocyte 424 
differentiation [38, 39]. PGC1-α expression is directly related with insulin sensitivity and is 425 
down regulated in muscle of type 2 diabetic subjects [39]. Therefore, a reduction in PGC1-α 426 
expression in the muscle of SRL-treated rats may account for the development of insulin 427 
resistance. Moreover, muscle specific mTORC1 loss is associated with a decrease in PGC1-α 428 
expression levels, and with a reduction in the expression of mitochondrial target genes 429 
including PGC-1α itself, as well as in oxidative metabolism [40-43]. 430 
 Since PTP1B is a negative regulator of insulin signaling, and its deletion has been coupled 431 
with improved insulin sensitivity, we evaluated how the in vivo treatment with these agents 432 
could affect its gene and protein expression in the various tissues. Interestingly, PTP1B 433 
protein level was increased in the CsA group in the liver but not in muscle or adipose tissue. 434 
Although PTP1B gene expression in the liver was increased by SRL treatment, no changes 435 
were observed in protein expression in liver, muscle or adipose tissue. Overexpression of 436 
PTP1B may result in systemic insulin resistance in mice [44-46].  However, PTP1B activity is 437 
also regulated at the phosphorylation level, as when Akt phosphorylates PTP1B at Ser50, the 438 
enzyme shows a decrease in its ability to dephosphorylate insulin receptors [47], which was 439 
not measured in these experiments. In addition, we have recently shown that SRL treatment 440 
contributes to lipid accumulation in the liver [48], a condition known to up regulate PTP1B 441 
expression [47], and that could have contributed to the increased PTP1B overexpression. 442 
Likewise, PTP1B overexpression in the presence of excess lipids may not directly cause 443 
insulin resistance unless it is accompanied by decreased PTP1B phosphorylation [47], which 444 
might explain the similarity of the GTT results between the vehicle and the SRL group. 445 
However, to our knowledge this is the first report showing alterations on PTP1B protein 446 
expression with CsA treatment. This increase in PTP1B protein expression may be linked to 447 
an increase in insulin resistance and gluconeogenesis as liver specific PTP1B -/- mice have 448 
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been shown to have decreased expression of gluconeogenic genes and increased hepatic 449 
insulin signaling [46], and were able to reverse glucose intolerance [49]. Assays to determine 450 
PTP1B activity should be considered in future studies with CsA treatment, as in diabetic rats, 451 
increased PTP1B levels and activity decrease glucose uptake and insulin signaling [50].  452 
To further elucidate the development of whole body glucose intolerance and the previously 453 
reported data showing that treatment with CsA or SRL impairs insulin-stimulated glucose 454 
uptake in epididymal adipose tissue [19, 23], we also analyzed protein expression and 455 
activation of important insulin signaling markers in muscle, liver and adipose tissue. While 456 
IRS-1 protein levels were significantly increased in the liver, but not in muscle and adipose 457 
tissue, a reduction in GLUT1 protein level was detectable in liver and muscle with the SRL 458 
treatment. No changes were observed in GLUT2 (liver) or GLUT4 (muscle and adipose 459 
tissue), the main insulin-stimulated transporter [51, 52], with either treatments. A decrease in 460 
GLUT1 protein expression with the SRL treatment might explain the reduction of the basal 461 
glucose uptake, observed by Pereira, Palming [20], Fuhrmann, Lopes [23] and Deblon, 462 
Bourgoin [27], while the increase in IRS-1 expression also observed by Takano, Usui [53] 463 
and Um, D'Alessio [54] might be a compensatory mechanism. In this study we cannot exclude 464 
the possibility that even though the GLUT4 protein expression was not different, its 465 
translocation to the membrane could be impaired, as it has been observed before in pre 466 
diabetic and diabetic states in fat [55, 56]. This experiment was not performed due to the lack 467 
of tissue, but should be addressed in future studies. Nonetheless, impaired glucose uptake in 468 
CsA-treated rats might be related with a reduced amount of GLUT4 in the plasma membrane 469 
as Pereira et al. (unpublished data) recently demonstrated that CsA treatment reduced the 470 
insulin-stimulated presence of GLUT4 in the plasma membrane of differentiated human pre-471 
adipocytes and L6 muscle cells. On the other hand, in the SRL group, glucose uptake might 472 
be decreased due to an impairment of the insulin signaling, as already demonstrated in human 473 
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and rat insulin sensitive cells [20, 21, 57, 58]. Moreover, the decrease in PGC1-α protein 474 
expression in the muscle of the SRL-treated group might also be responsible for a decrease in 475 
insulin sensitivity, as PGC1-α increases the expression of the insulin-sensitive transporter 476 
GLUT4 in the muscle [59, 60]. Insulin initiates intracellular signaling when it binds to the 477 
insulin receptor, phosphorylating its tyrosine residues. In our work, phosphorylation of the 478 
insulin receptor at Tyr1146 residue was decreased in the SRL group both in liver and adipose 479 
tissue. Moreover SRL also impaired phosphorylation of the key protein, Akt at Ser473 and 480 
Thr308 residues in liver and adipose tissue, while no alterations were observed by the CsA 481 
treatment, previously demonstrated both in vitro and in vivo [61-63]. Sarbassov, Guertin [64] 482 
have also shown that mTOR kinase and rictor are essential for phosphorylation of Akt Ser473 483 
and SRL reduces insulin phosphorylation of IRS-1 on Tyr residues [65], which is in 484 
accordance with our results at least in muscle. Moreover, Shivaswamy, Bennett [21] observed 485 
recently that SRL treatment reduces insulin-stimulated phosphorylation of Akt in liver, 486 
muscle and fat. On the other hand, insulin sensitivity may also be affected by intracellular 487 
lipid accumulation, through impairment of IRS-1-PI3K-Akt signaling pathways [63, 66], 488 
which may also be the case, as our group already demonstrated that after 3 weeks of treatment 489 
with SRL, there is an accumulation of TGs in liver and muscle [48]. Impaired Akt activation 490 
leads also to a decrease in phosphorylation of AS160, an important substrates of Akt that 491 
controls the translocation of glucose transporters to the plasma membrane. In agreement with 492 
other studies (Pereira et al., unpublished data), [20, 27] these results reveal that SRL treatment 493 
inhibits activation of Akt in response to insulin, affecting glucose metabolism in skeletal 494 
muscles and adipocytes. As expected, the mTOR pathway was blocked by SRL treatment, as 495 
evidenced by the lack of phosphorylation of its downstream target, the p70S6K.   496 
Taken together, these data indicate that CsA affects glucose metabolism, by increasing 497 
gluconeogenic factors in liver and SRL mainly by impairing the insulin signaling cascade 498 
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pathway in peripheral tissues, which ultimately can affect glucose uptake (Figure 8). These 499 
effects might contribute to the development of insulin resistance after immunosuppressive 500 
therapy, and caution is required when choosing the therapy to apply to patients, in order to 501 
prevent the development of NODAT. 502 
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Figure Legends  709 
 710 
Figure 1. Effects of vehicle, CsA, and SRL treatment during a GTT (A), an ITT (B), as well 711 
as, fasting serum glucose (C), insulin (D) C-peptide (E), and the glucose clearance rate in the 712 
urine (F). Rats were treated with CsA and SRL for 3 weeks and fasted for 16 hours before the 713 
glucose tolerance test. Glucose levels were measured at time point 0, and after an 714 
intraperitoneal injection of glucose (2 g/kg BW) at 15, 30, 60, and 120 minutes and respective 715 
area under the curve. For the ITT, rats were fasted for 6 hours and glucose levels were 716 
measured at time point 0, and after an intraperitoneal injection of insulin (1U/kg BW) at 15, 717 
30, 45, 60 and 90 minutes and respective area under the curve. Fasting serum glucose, insulin 718 
and C-peptide levels were measured. Urine collection was done 24 hours prior to sacrifice. 719 
Data are presented as mean ± SEM (n=6-8/group) *p<0.05, ** p<0.01***p<0.001 vehicle vs. 720 
CsA group; & p<0.05 vehicle vs. SRL group;  ###p<0.001 CsA vs. SRL group. CsA – 721 
Cyclosporine A; SRL – Sirolimus;  722 
 723 
Figure 2. Gluconeogenic gene and protein expression in liver, after a 3 week-treatment period 724 
with CsA or SRL. Relative mRNA expression levels were determined by Real-time PCR 725 
(n=8). Protein expression levels were determined by western blotting (three to five 726 
independent experiments) for PGC1-α, FOXO1 and PTP1B (A) and G6Pase, PEPCK and GK 727 
(B). Data are presented as mean ± SEM. *p<0.05 vehicle vs. CsA or SRL group; #p<0.05 CsA 728 
vs. SRL group. CsA – Cyclosporine A; SRL – Sirolimus; PGC1-α - peroxisome proliferator-729 
activated receptor γ coactivator 1, FOXO1- forkhead box O1, PTP1B -protein tyrosine 730 
phosphatase 1B, G6Pase - Glucose-6-phosphatase, PEPCK- Phosphoenolpyruvate 731 
carboxykinase, GK - Glucokinase. 732 
 733 
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Figure 3. Expression of genes and proteins of the insulin signaling pathway in liver after a 3 734 
week-treatment period, with CsA or SRL. Relative mRNA expression levels were determined 735 
by Real-time PCR (n=8). Protein expression levels were determined by western blotting 736 
(three to five independent experiments) for IRS-1, GLUT1 and GLUT2 (A). Phosphorylation 737 
levels of IRS-1 Tyr612, protein expression levels of PI3K p85 subunit and GLUT2 and 738 
phosphorylation levels of pAkt Ser473 and Thr308, p70S6K Thr412/424, mTOR Ser2448, 739 
and AS160 Thr642, after stimulation with insulin (B).  *p<0.05 vehicle vs. CsA or SRL 740 
group; *p<0.05, **p<0.01 basal vs. insulin; CsA – Cyclosporine A; SRL – Sirolimus; IRS-1 – 741 
Insulin Receptor substrate 1;  GLUT1 – Glucose transporter 1 and GLUT2 - Glucose 742 
transporter 2; PI3K - Phosphatidylinositide 3-kinase. 743 
 744 
Figure 4. Gene and protein expression in muscle after a 3-week treatment period with CsA or 745 
SRL. Relative mRNA expression levels were determined by Real-time PCR (n=8). Protein 746 
expression levels were determined by western blotting (three to five independent 747 
experiments) for PGC1-α, FOXO1 and PTPB1. Data are presented as mean ± SEM, *p<0.05 748 
vehicle vs. CsA or SRL group; #p<0.05 CsA vs. SRL group. CsA – Cyclosporine A; SRL – 749 
Sirolimus; PGC1-α - peroxisome proliferator-activated receptor γ coactivator 1, FOXO1- 750 
forkhead box O1, PTP1B -protein tyrosine phosphatase 1B. 751 
 752 
Figure 5. Expression of genes and proteins of the insulin signaling cascade in muscle after a 753 
3-week treatment period, with CsA or SRL. Relative mRNA expression levels were 754 
determined by Real-time PCR (n=8). Protein expression levels were determined by western 755 
blotting (three to five independent experiments) for IRS-1, GLUT1 and GLUT4 (A). 756 
Phosphorylation levels of IRS-1 Tyr612, protein expression levels of PI3K p85 subunit, 757 
Page 31 of 41
Ac
ce
pte
d M
an
us
cri
pt
31 
 
GLUT4, and phosphorylation levels of pAkt Ser473 and Thr308, p70S6K Thr421/424, mTOR 758 
Ser2448, and AS160 Thr642, after stimulation with insulin (B). Data are presented as mean ± 759 
SEM.  *p<0.05 vehicle vs. CsA group; *p<0.05 basal vs. insulin ; CsA - Cyclosporine A; 760 
SRL – Sirolimus; IRS-1 – Insulin Receptor substrate 1; GLUT1 – Glucose transporter 1 and 761 
GLUT4 - Glucose transporter 4; PI3K - Phosphatidylinositide 3-kinase. 762 
 763 
Figure 6. Gene and protein expression in perirenal adipose tissue after a 3-week treatment 764 
period, with CsA or SRL. Relative mRNA expression levels were determined by Real-time 765 
PCR (n=8). Protein expression levels were determined by western blotting (three to five 766 
independent experiments) for PGC1-α, FOXO1 and PTP1B. Data are presented as mean ± 767 
SEM , *p<0.05 vehicle vs. SRL group; CsA – Cyclosporine A; SRL – Sirolimus; PGC1-α - 768 
peroxisome proliferator-activated receptor γ coactivator 1,  FOXO1- forkhead box O1, PTP1B 769 
-protein tyrosine phosphatase 1B. 770 
 771 
Figure 7. Expression of genes and proteins of the insulin signaling cascade in epididymal 772 
adipose tissue after a 3-week treatment period, with CsA or SRL. Relative mRNA expression 773 
levels were determined by Real-time PCR (n=8). Protein expression levels were determined 774 
by western blotting (three to five independent experiments) for IRS-1, GLUT1 and GLUT4. 775 
Phosphorylation levels of IRS-1 Tyr612, protein expression levels of PI3K p85 subunit, 776 
GLUT4 and phosphorylation levels of pAkt Ser473 and Thr308, p70S6K Thr421/424, mTOR 777 
Ser2448, and AS160 Thr642, after stimulation with insulin. Data are presented as mean ± 778 
SEM, *p<0.05 basal vs. insulin. CsA – Cyclosporine A; SRL – Sirolimus; IR – Insulin 779 
receptor; IRS-1 – Insulin Receptor substrate 1; PI3K - Phosphatidylinositide 3-kinase; 780 
GLUT1 – Glucose transporter 1 and GLUT4 - Glucose transporter 4. 781 
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 782 
Figure 8. Scheme summarizing the effects of CsA and SRL on the gluconeogenesis and 783 
insulin signaling in muscle and adipose tissue.  Red arrows correspond to CsA; Blue arrows 784 
correspond to SRL. ↑, increase; ↓, decrease.  785 
 786 
 787 
 788 
 789 
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 792 
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